Denali Therapeutics Inc. Stock News

Denali Therapeutics Inc (DNLI) shares closed today at 1.7% above its 52 week low of $40.87, giving the company a market cap of $5B. The stock is currently down 6.8% year-to-date, down 48.1% over the past 12 months, and up 93.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 28.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -46.3% The company's stock price performance over the past 12 months lags the peer average by 257.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -171.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Denali Therapeutics Inc (DNLI) shares closed today at 1.7% above its 52 week low of $40.87, giving the company a market cap of $5B. The stock is currently down 6.8% year-to-date, down 43.7% over the past 12 months, and up 93.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 28.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -46.3% The company's stock price performance over the past 12 months lags the peer average by 281.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 948.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities analysts expect Denali Therapeutics Inc. (NASDAQ:DNLI) to post earnings of ($0.41) per share for the current quarter, according to Zacks. Seven analysts have provided estimates for Denali Therapeutics earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.71). Denali Therapeutics posted earnings per share of $1.91 []

Equities analysts forecast that Denali Therapeutics Inc. (NASDAQ:DNLI) will post earnings per share (EPS) of ($0.41) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Denali Therapeutics earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.12). Denali Therapeutics reported earnings per share of $1.91 in the []

Denali Therapeutics (NASDAQ:DNLI) and Aziyo Biologics (NASDAQ:AZYO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of recent ratings and recommmendations for Denali Therapeutics and Aziyo []

Denali Therapeutics Inc. (NASDAQ:DNLI)s share price reached a new 52-week low on Monday after an insider sold shares in the company. The stock traded as low as $41.12 and last traded at $42.45, with a volume of 2828 shares changing hands. The stock had previously closed at $42.59. Specifically, CEO Ryan J. Watts sold 18,333 []

Aziyo Biologics (NASDAQ:AZYO) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership. Risk and Volatility Aziyo Biologics has a beta of 0.56, indicating that its stock price is [] The post Aziyo Biologics (NASDAQ:AZYO) & Denali Therapeutics (NASDAQ:DNLI) Financial Contrast appeared first on ETF Daily News .

Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts sold 18,333 shares of the companys stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $44.92, for a total value of $823,518.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be []

Related Stocks: DNLI ,

Polianta Ltd bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,800 shares of the companys stock, valued at approximately $998,000. Other large investors also recently bought and sold shares of the company. AXA []

Wall Street brokerages expect Denali Therapeutics Inc. (NASDAQ:DNLI) to post earnings per share (EPS) of ($0.41) for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Denali Therapeutics earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.73). Denali Therapeutics posted earnings per []

Analysts predict that Denali Therapeutics Inc. (NASDAQ:DNLI) will post earnings of ($0.41) per share for the current quarter, according to Zacks. Seven analysts have made estimates for Denali Therapeutics earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.73). Denali Therapeutics reported earnings per share of $1.91 during the same quarter last year, []

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been given a consensus recommendation of Buy by the ten analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokerages that have []

Marshall Wace North America L.P. lowered its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 95.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,915 shares of the companys stock after selling 263,011 shares during the period. Marshall Wace North America L.P.s holdings in []

Arthur M. Cohen & Associates LLC increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 121.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 7,547 shares of the companys stock after purchasing an additional 4,139 shares during the quarter. Arthur M. Cohen & Associates LLCs holdings in Denali Therapeutics were worth $381,000 []